Gadeta has raised €7M in a series A round, which will fuel the clinical development of its novel TCR platform, starting with a leukemia cell therapy trial.
Gadeta is a spin-out of immuno-oncology research at the University Medical Center Utrecht (UMC Utrecht). It was founded in 2015 by the researchers and Utrecht Holdings, the technology transfer arm of Utrecht University, and received seed funding from Medicxi Ventures — the recently rebranded Index Ventures life sciences VC.
Gadeta has now raised €7M in a series A round, and snatched a new investor — Baxalta Ventures, which will have one of its partners joining the supervisory board.
But what is Gadeta developing exactly? Its immuno-oncology strategy is based on the work of Jürgen Kuball, one of the founders. He researched γδ T-cells — a small subgroup of T-cells that express a unique T-cell receptor (TCR). His company creates optimised TCRs with enhanced anti-cancer reactivity.